Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have earned an average rating of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $47.80.

A number of analysts have recently commented on TWST shares. Barclays dropped their price objective on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, October 2nd. Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Monday, August 4th. Evercore ISI lowered their price objective on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Stephens assumed coverage on shares of Twist Bioscience in a report on Monday. They issued an “overweight” rating and a $41.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday, October 8th.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 31,379 shares of the company’s stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $986,555.76. Following the completion of the sale, the chief executive officer directly owned 738,809 shares of the company’s stock, valued at approximately $23,228,154.96. This represents a 4.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Adam Laponis sold 5,517 shares of the firm’s stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $31.44, for a total transaction of $173,454.48. Following the completion of the transaction, the chief financial officer directly owned 111,008 shares of the company’s stock, valued at $3,490,091.52. This represents a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 115,715 shares of company stock valued at $3,650,554 over the last ninety days. Company insiders own 3.01% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. GAMMA Investing LLC boosted its position in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after acquiring an additional 303 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after purchasing an additional 302 shares during the period. Geneos Wealth Management Inc. purchased a new position in Twist Bioscience during the second quarter valued at approximately $97,000. CWM LLC increased its stake in Twist Bioscience by 61.4% in the 3rd quarter. CWM LLC now owns 4,331 shares of the company’s stock valued at $122,000 after buying an additional 1,648 shares during the period. Finally, Bayforest Capital Ltd lifted its position in Twist Bioscience by 49.3% in the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock worth $191,000 after buying an additional 1,604 shares in the last quarter.

Twist Bioscience Stock Down 4.0%

TWST stock opened at $31.57 on Tuesday. The firm’s 50-day moving average is $29.05 and its two-hundred day moving average is $31.79. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -21.77 and a beta of 2.43. Twist Bioscience has a 52 week low of $24.07 and a 52 week high of $55.33.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07. The firm had revenue of $96.06 million for the quarter, compared to analysts’ expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. On average, analysts forecast that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.